Identification of novel small chemical compounds that inhibit Ebola virus VP40-mediated virus-like particle production

The central role of Ebola virus (EBOV) VP40 in nascent virion assembly and budding from infected host cells makes it an important therapeutic target. Previously, we reported two novel chemical compounds (NUSU#1 and NUSU#2) that inhibit EBOV VP40-mediated virus-like particle (VLP) production. In this study, we aimed to develop and identify novel synthetic compounds derived from NUSU#1. Forty-five compounds were synthesized and examined for their effects in vitro. Through cell viability and screening assays that we previously developed and reported, five novel synthesized compounds were selected for their inhibitory effects on EBOV VP40-mediated VLP production. Although none of them showed a stronger inhibitory effect on VLP production than NUSU#1, four of the five selected compounds exhibited a statistically significant reduction in EBOV VP40-mediated VLP production compared with the control treatment using a VLP assay.

Authors

Institutions

Publication Details

Journal
Virus Research
Published
2026-01-03
DOI
https://doi.org/10.1016/j.virusres.2026.199684
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Identification of novel small chemical compounds that inhibit Ebola virus VP40-mediated virus-like particle production

Satoshi Mizuta, Jiro Yasuda, Tomoko Tsuruta, Ayako Izumisawa et al.
Virus Research
Viral Infections and Outbreaks Research
article

Identification of novel small chemical compounds that inhibit Ebola virus VP40-mediated virus-like particle production

Satoshi Mizuta, Jiro Yasuda, Tomoko Tsuruta, Ayako Izumisawa, Shuzo Urata
article en

Abstract

The central role of Ebola virus (EBOV) VP40 in nascent virion assembly and budding from infected host cells makes it an important therapeutic target. Previously, we reported two novel chemical compounds (NUSU#1 and NUSU#2) that inhibit EBOV VP40-mediated virus-like particle (VLP) production. In this study, we aimed to develop and identify novel synthetic compounds derived from NUSU#1. Forty-five compounds were synthesized and examined for their effects in vitro. Through cell viability and screening assays that we previously developed and reported, five novel synthesized compounds were selected for their inhibitory effects on EBOV VP40-mediated VLP production. Although none of them showed a stronger inhibitory effect on VLP production than NUSU#1, four of the five selected compounds exhibited a statistically significant reduction in EBOV VP40-mediated VLP production compared with the control treatment using a VLP assay.

Virus ResearchVol. 364
Nagasaki Medical Center (JP), Nagasaki University (JP)
Openalex Percentile: Top 99%
Viral Infections and Outbreaks Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Identification of novel small chemical compounds that inhibit Ebola virus VP40-mediated virus-like particle production — Satoshi Mizuta, Jiro Yasuda, et al. · Virus Research (2026) | TGRS Research Map | TGRS